Let's see how they do that:
Ad for Drug Is Challenged - Published: February 26, 1991 Genentech Inc. filed a lawsuit today in United States District Court here accusing SmithKline Beecham P.L.C. of false advertising.
SMITHKLINE AND ROHM & HAAS TO CLEAN UP TOXIC SITE - Published: September 18, 1992 The Rohm & Haas Company and SmithKline Beecham P.L.C. have agreed to spend about $125 million to clean up the former Whitmoyer Laboratories site in Myerstown, Pa., the Justice Department said. Whitmoyer Laboratories manufactured veterinary pharmaceuticals from 1934 to 1984. During that time, toxic materials -- aniline and soluble arsenic compounds -- were produced, stored and disposed at the site. The Whitmoyer installation is one of the Environmental Protection Agency's so-called Superfund cleanup sites.
Glaxo-F.D.A. Dispute - Published: March 8, 1993 The United States Food and Drug Administration has accused Glaxo Holdings P.L.C. of illegally promoting its top-selling ulcer drug Zantac, The Sunday Times of London reported today. The article said the F.D.A. sent a letter to Glaxo in January warning that its advertising for Zantac had "statements, suggestions or implications that are false and/or misleading."
F.D.A. PANELS REJECT SMITHKLINE DRUG REQUEST - Published: September 10, 1993 Two advisory committees to the Food and Drug Administration yesterday turned down a request by SmithKline Beecham P.L.C. to recommend F.D.A. approval of its prescription heartburn drug Tagamet for over-the-counter sale. The panels said the company's tests did not show Tagamet was superior to placebos.
Seven Big Drug Makers Are Sued Over Pricing - Published: October 15, 1993 Struggling with growing competition from cheaper mail-order pharmacies and health maintenance organizations, 20 drugstore companies filed a lawsuit yesterday accusing large drug makers of price fixing and Federal antitrust violations. The other defendants are the American Home Products Corporation, SmithKline Beecham, the Ciba-Geigy Corporation, the Searle unit of the Monsanto Corporation and Glaxo Holdings P.L.C.
SmithKline Ulcer Drug Challenged - Published: July 29, 1994 SmithKline Beecham P.L.C. was dealt a second setback today in its regulatory quest to turn its prescription ulcer drug Tagamet into an over-the-counter treatment for heartburn.
Glaxo to Alter Drug Label - Published: August 17, 1994 The Food and Drug Administration has ordered Glaxo Holdings P.L.C. to change the labels of its anti-migraine drug Imitrex to include information about the death of an American woman who used the drug, Glaxo said today.
F.T.C. TO REVIEW SMITHKLINE'S DIVERSIFIED PURCHASE - Published: November 15, 1994 A week after restricting a major drug industry merger, the Federal Trade Commission is examining another -- the purchase by SmithKline Beecham P.L.C. of Diversified Pharmaceutical Services Inc
Drug Makers Settle Suit on Price Fixing - Published: February 10, 1996 Fifteen big drug companies formally agreed yesterday to pay more than $408 million to settle a class action lawsuit charging them with conspiring to illegally fix prices that they charged to thousands of independent pharmacies. In the settlement, which is subject to approval by a Federal district judge in Chicago, the 15 companies agreed to pay more than $388 million in cash. One of the defendants, SmithKline Beecham P.L.C. of London, agreed to supply the plaintiffs with a generic version of cimetidine, SmithKline's Tagamet brand ulcer treatment, valued at $20 million, as well as $30 million in cash.
SmithKline Beecham in Settlement With U.S. - Published: September 7, 1996 In the latest big settlement by a clinical laboratory company of Federal Medicare fraud charges, SmithKline Beecham P.L.C. expects to pay the Government about $300 million this year, without admitting any wrongdoing. Analysts said the Laboratory Corporation of America also expects to settle similar charges by the end of the year.
Merck Files Suit Over Vaccine Distribution - Published: December 25, 1996 Merck & Company, saying it has exclusive rights to distribute a chicken pox vaccine in the United States and Canada, has sued four affiliates of SmithKline Beecham P.L.C. in an effort to block them from distributing their vaccine in the United States.
37 Health Insurers Suing SmithKline - Published: August 25, 1997 SmithKline Beecham P.L.C. has been sued by 37 private health insurers contending that the company's clinical laboratory division overbilled them by hundreds of millions of dollars.
Concerns Grow Over Reactions To Lyme Shots - Published: November 21, 2000 Federal health authorities are investigating whether some people who received the vaccine against Lyme disease later developed severe cases of arthritis and even Lyme disease itself as a result. The Food and Drug Administration has received reports of such problems, mainly from doctors and researchers in the Northeast. The vaccine, made by SmithKline Beecham Biologicals, a subsidiary of the British pharmaceutical giant SmithKline Beecham, was approved by the drug agency two years ago, and about 440,000 Americans have received it. SmithKline Beecham defends it as safe.
U.S. Looking at SmithKline Effort to Block Generic Drug - Published: December 7, 2000 The Federal Trade Commission is investigating whether SmithKline Beecham, the British drug company, has engaged in illegal trade practices by keeping competitors from selling generic, lower-cost versions of Paxil, its popular antidepressant, according to court papers.
5 Drug Makers Use Material With Possible Mad Cow Link - Published: February 8, 2001 For the last eight years, the Food and Drug Administration has repeatedly asked pharmaceutical companies not to use materials from cattle raised in countries where there is a risk of mad cow disease. All five vaccine makers, which include GlaxoSmithKline, Aventis and American Home Products, have now agreed to stop using the suspect materials, which include blood, fetal calf serum and meat broth.
DRUG MAKERS DROP SOUTH AFRICA SUIT OVER AIDS MEDICINE - Published: April 20, 2001 Bowing to mounting public pressure, the pharmaceutical industry today dropped its legal effort to prevent South Africa from importing cheaper anti-AIDS drugs and other medicines. The companies that began the negotiations that led to today's settlement were Bristol-Myers Squibb and Merck, both of the United States, GlaxoSmithKline of Britain, Hoffmann-La Roche of Switzerland and Boehringer Ingelheim of Germany.
Genentech Wins GlaxoSmithKline Dispute - Published: May 5, 2001 Genentech Inc. said yesterday that it had defeated a patent infringement suit brought by GlaxoSmithKline P.L.C. over two oncology drugs.
Jury Awards $6.4 Million In Killings Tied to Drug - Published: June 8, 2001 A Wyoming jury has awarded $6.4 million to the family of a man who killed three relatives and himself after taking the antidepressant Paxil. Charles F. Preuss, a lawyer for the manufacturer, GlaxoSmithKline said the verdict on Wednesday was a surprise.
Glaxo Is Sued Over Antidepressant - Published: August 27, 2001 A lawsuit accuses Glaxo SmithKline, the maker of the popular antidepressant Paxil, of concealing evidence that the drug can be addictive.
IN STUDY, LILLY CALLS ITS ANTIDEPRESSANT MORE EFFECTIVE - Published: November 20, 2001 Eli Lilly has released clinical data showing that its experimental antidepressant, duloxetine, was more effective in reducing symptoms of depression than GlaxoSmithKline's Paxil.
Rockies: Montana: Suit Against Drug Companies - Published: February 26, 2002 The state attorney general sued 18 drug makers and marketers, accusing them of illegally inflating prices and costing the state and consumers tens of millions of dollars. The scheme hurt taxpayers because they finance the Medicaid and Medicare programs that were forced to pay the exaggerated drug prices, Attorney General Mike McGrath, left, said. The lawsuit names Abbott Laboratories; American Home Products; Amgen; AstraZeneca; Aventis Pharma and Hoechst Marion Roussel, both owned by Aventis; Baxter Pharmaceutical Products; Bristol-Myers Squibb; Eli Lilly; Chiron; Dey; GlaxoSmithKline and SmithKline Beecham, which have merged
Sole Lyme Vaccine Is Pulled Off Market - Published: February 28, 2002 With tick season approaching, the maker of the nation's only vaccine against Lyme disease pulled it off the market, citing poor sales. The vaccine, Lymerix, had caused controversy in recent years, as patients said they were sickened by it and asked the government to restrict sales. Some filed lawsuits against the maker, GlaxoSmithKline.
RULING FAVORS GENERIC ANTIDEPRESSANT FROM ANDRX - Published: March 2, 2002 The Andrx Group said a judge ruled that its generic version of GlaxoSmithKline's Wellbutrin antidepressant did not infringe a Glaxo patent
JUDGE ALLOWS A GENERIC VERSION OF GLAXO ANTIBIOTIC - Published: March 14, 2002 The British drug maker GlaxoSmithKline said yesterday that a judge had ruled in favor of Teva Pharmaceutical Industries of Israel in Teva's bid to market a generic version of Glaxo's antibiotic Augmentin in America.
Warnings Added To Diabetes Drugs - Published: April 27, 2002 GlaxoSmithKline and Eli Lilly & Company have added warnings about heart and liver risks to the labels of their diabetes drugs, which are similar to a medication that was withdrawn from the market in 2000 because of links to fatal liver damage.
Judge Orders Drug Company To Alter Ads - Published: August 21, 2002 Federal Judge Mariana R Pfzelzer orders GlaxoSmithKline to stop saying in its advertisements for Paxil, top-selling antidepressant, that drug is 'nonhabit-forming'
Asthma Drug Health Risks Are Suspected - Published: January 24, 2003 GlaxoSmithKline said yesterday that Serevent, one of its popular asthma drugs, might pose a risk of death and serious asthma-related illness in some patients.
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
1 comment: